Treace Medical Concepts, Inc. (TMCI)
NASDAQ: TMCI · IEX Real-Time Price · USD
10.63
-0.03 (-0.23%)
Apr 30, 2024, 2:18 PM EDT - Market open
Treace Medical Concepts Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TMCI stock have an average target of 19.58, with a low estimate of 11 and a high estimate of 27.5. The average target predicts an increase of 84.28% from the current stock price of 10.63.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 22, 2023.
Analyst Ratings
The average analyst rating for TMCI stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $12 → $16 | Strong Buy | Maintains | $12 → $16 | +50.59% | Dec 22, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $30 → $14 | Buy | Maintains | $30 → $14 | +31.76% | Nov 13, 2023 |
| Stifel | Stifel | Strong Buy Maintains $28 → $11 | Strong Buy | Maintains | $28 → $11 | +3.53% | Nov 10, 2023 |
| Truist Securities | Truist Securities | Strong Buy Maintains $17 → $12 | Strong Buy | Maintains | $17 → $12 | +12.94% | Nov 10, 2023 |
| Stifel | Stifel | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +163.53% | Oct 2, 2023 |
Financial Forecast
Revenue This Year
227.27M
from 187.12M
Increased by 21.46%
Revenue Next Year
268.35M
from 227.27M
Increased by 18.08%
EPS This Year
-0.95
from -0.81
EPS Next Year
-0.83
from -0.95
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 234.8M | 281.9M | 339.5M | 403.8M | 486.4M |
| Avg | 227.3M | 268.4M | 313.4M | 392.3M | 472.5M |
| Low | 217.9M | 249.7M | 287.4M | 376.9M | 453.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 25.5% | 24.1% | 26.5% | 28.9% | 24.0% |
| Avg | 21.5% | 18.1% | 16.8% | 25.2% | 20.4% |
| Low | 16.5% | 9.9% | 7.1% | 20.3% | 15.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.88 | -0.72 | -0.64 | 0.04 | 0.41 |
| Avg | -0.95 | -0.83 | -0.79 | 0.04 | 0.40 |
| Low | -0.99 | -1.01 | -1.10 | 0.04 | 0.38 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 903.7% |
| Avg | - | - | - | - | 875.0% |
| Low | - | - | - | - | 836.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.